Zusammenfassung
Bereits 1877 hat Squire gefunden, dass Goapuder eine Wirkung auf die Psoriasis hat. Als wirksame Substanz stellte sich Chrysarobin heraus. Da es sich bei Goapuder um eine Droge handelte und zudem während des 1. Weltkrieges die Versorgung ins Stocken kam, war es ein Fortschritt, als Galewski (1916) Dithranol synthetisierte, eine Substanz mit ähnlicher Struktur wie Anthrarobin. Dithranol ist somit eine der ältesten Pharmaka, die in der externen Therapie eingesetzt werden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Ameen M, Chu AC (1999) Treatment of vitiligo with topical calcipotriol. Br J Dermatol 141 Suppl 55: 75
Anigbogu ANC, Williams AC, Barry BW (1996) Permeation characteristics of 8 methoxypsoralen through human skin relevance to clinical treatment. J Pharm Pharmacol 48: 356–366
Baker BS, Swain AF, Griffiths CEM, Leonard JN, Fry L, Valdimarsson H (1985) The effects of topical treatment with steroids or dithranol on epidermal T lymphocytes and dendritic cells in psoriasis. Scand J Immunol 22: 471–477
Barach-Buhles M, Röchling A, El Gammal S, Altmeyer P (1996) The effect of fumaric acid esters and dithranol on acanthosis and hyperproliferation in psoriasis vulgaris. Acta Derm Venereol (Stockh) 76: 190–193
Barker JNWN, Ashton R, Marks R, Harris RI, Berth-Jones J (1999) Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo controlled, double blind, dose finding study with active comparator. Br J Dermatol 141: 274–278
Behrens S, Reuther T, Kobyletzki G, Altmeyer P, Kerscher M (1997) Die PUVA Turbantherapie. Hautarzt 48: 842–843
Behrens S, Leiter U, Grundmann-Kollmann M, Gruss C, Peter RU, Kerscher M (1998) PUVA Ölbad Therapie mit einem pflanzlich mineralischen Mischpräparat. Akt Dermatol 24: 336–340
Berth-Jones J, Chu AC, Dodd WAH, Ganpule M, Griffith WAD, Haydly RP, Kleter MR, Murray SJ, Rogers S, Ivergensen HJ (1992) A multicentre parallel group comparison of calcipotriol ointment and short term dithranol therapy in chronic plaque psoriasis. Br J Dermatol 127: 266–271
Berth-Jones J, Bourke J, Iqdal SJ, Hudchinson PE (1993) Urine calcium excretion during treatment of psoriasis with topical calcipotriol. Br J Dermatol 129: 411–414
Bourke JF, Berth-Jones J, Iqdal SJ, Hutchinson PE (1993a) High dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol 129: 74–76
Bourke JF, Berth-Jones J, Hutchinson PE (1993b) Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clin Exp Dermatol 18: 504–506
Bruse S, Epinette WW, Funicella T, Son A, Jones EL, Los R, McPhee ME, Whitemore C (1994) Comparative study of calcipotriene (MC 903) ointment and fluocinoide ointment in the treatment of psoriasis. J Am Acad Dermatol 31: 755–759
Bruynzeel DP, Hol CW, Nieboer C (1992) Allergic contact dermatitis to calcipotriol. Br J Dermatol 127: 66
Chang A, Alkemade H, Kerkhof van de PCM (1989) Dithranol modulates the leukotriene B4, induced intraepidermal accumulation of polymorphonuclear leukocytes. J Invest Dermatol 92: 806–808
Child EJ, Bellaney GJ, Mc Keon S, Seed P, Basarab T, Setterfield J, Peloux-Monage du H, Eady RAJ (1999) Assessment of a modified dithranol regime for inpatient treatment of psoriasis. Br J Dermatol 141 Suppl 59: 71–72
Cripps DJ, Lowe NJ (1979) Photochemotherapy for psoriasis remission times, psoralens and UV-A and combined photochemotherapy with anthralin. Clin Exp Dermatol 4: 477–483
Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G, Goldin D, Gratton D, Hendersson CA, Holden CA, Madin US, Ortonne JP, Youns M (1992) Comparative study of calcipotriol (MC903) ointment and betamethasone 17 -valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 26: 736–743
Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N (1996) Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol 135: 390–393
Delaney C, Liao W, Cohen M, Fancher M, Kripalani K, Uderman H, Stolz R, Siskin SB (1996) Percutaneous absorption of calcipotriene (calcipotriol) in normal volunteers and psoriatic patients after a single dose of 3H calcipotriene following multiple dose treatment with non radiolabeled calcipotriene 0.005% ointment. J Invest Dermatol Symp Proc 1: 112
Dykes PJ, Roberts GP, Marks R (1981) Anthralin cytotoxicity. Br J Dermatol 105 Suppl 20: 43–45
Elbrecht C, Landes E (1983) Untersuchungen über die Wirksamkeit einer kombinierten Psoriasis Behandlung mit Dithranol und UV-B (SUP). Z Hautkr 58: 387–397
Farkas B, Dobozy A, Horváth A, Hunyadi J, Schneider I (1999) Comparison of tacalcitol ointment with short contact dithranol therapy in the treatment of psoriasis vulgaris: a randomized multicentre open prospective study on efficacy and safety. J Dermatol Treatm l0: 93–99
Fiore M (1990) Practical aspects of anthralin therapy. Cutis 46: 351–354
Fischer T (1998) Topical PUVA and bath PUVA. In Roenigk HH Jr, Maibach HI (eds). Psoriasis. Marcel Dekkers, New York Basel Hong Kong, pp 565–575
Fransje ACM, Castelijns FACM, Gerritsen MJP, Vlijmen-Willems IMJJ van, Erp PH van, Kerkhof CM van de (1999) Proliferation is the main epidermal target in the treatment of psoriatic plaques with once daily application of tacalcitol ointment. Acta Derm Venereol (Stockh) 79: 111–114
Frappaz A, Thivolet J (1993) Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 3: 331–334
Fulton JE, Willis I (1968) Photoallergy to methoxsalen. Arch Dermatol 98: 445–450
Galewsky E (1916) Über Cignolin, ein Ersatzpräparat des Chrysarobin. Dermatol Monatsschr 62: 113–115
Gehring W, Ghyczy M, Gloor M, Scheer T, Röding J (1992a) Enhancement of the penetration of dithranol and increase of effect of dithranol on the skin by liposomes. Arzneimittelforschung 42: 982–985
Gehring W, Scheer T, Gloor M (1992b) Die Bedeutung der Rezepturgrundlage für die Erythembildung durch Dithranol. Z Hautkr 67: 128–135
Gehring W, Klein M, Gloor M (1994) Liposomen als Träger von Dithranol bei der Behandlung der Psoriasis vulgaris. Z Hautkr 69: 451–453
Gerittsen MJP, Boezeman JBM, Vlijmen-Willems JMJJ van, Kerkhof PCM van de (1994) The effect of tacalcitol (1,24 (OH)2 D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo controlled double blind study. Br J Dermatol 131: 57–63
Glade CP, Erp PEJ van, Hooijdonk CAEM van, Elbers ME, Kerkhof UCM van de (1995) Topical treatment of psoriatic plaques with ía,25 - dihydroxyvitamin D3: a multiparameter flow cytometrical analysis of epidermal growth, differentiation and inflammation. Acta Derm Venereol (Stockh) 75: 381–385
Gloor M, Graf R, Wirth H, Landau M (1983) Untersuchungen zur Wirkungsweise einer Psoriasisbehandlung mit Dithranol im Vergleich zu einer Kombinationsbehandlung mit Dithranol und einem Kortikosteroid. Hautarzt 34: 500–503
Gómez MI, Azana JM, Arranz I, Harto A, Ledo A (1995) Plasma levels of 8 methoxypsoralen after bath PUVA for psoriasis: relationship to disease severity. Br J Dermatol 133: 37–40
Gray JD, Bottomley W, Layton AM, Cotteril JA, Monteriro E (1992) The use of calcipotriol in HIV related psoriasis. Clin Exp Dermatol 17: 342–343
Grossmann RM, Thivolet J, Claudy A, Souteyrand P, Guilhor JJ, Thomas P, Amblard P, Belaich S de, Belilovsky C, Brassine M de la, Martinet C, Bazex JA, Beylot C, Combermale P, Lambert D, Ostojnic A, Denooeus JP, Lauret PH, Vailant L, Weber M, Pamphile R, Dubertret L (1994) A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low dose cyclosporine: results of a multicenter placebo controlled study. J Am Acad Dermatol 31: 68–74
Groot AC de, Nater JP (1981) Contact allergy to dithranol. Contact Dermatitis 7: 5–8
Grundmann-Kollmann M, Behrens S, Peter RU, Kerscher M (1999a) Treatment of severe recal-citrant dermatoses of the palms and soles with PUVA bath versus PUVA cream therapy. Photodermatol Photoimmunol Photomed 15: 87–89
Grundmann-Kollmann M, Leiter U, Behrens S, Gottlöbe P, Mooser G, Krähn G, Kerscher M (1999b) The time course of phototoxicity of topical PUVA: 8 methoxypsoralen cream PUVA versus 8 methoxypsoralen gel PUVA. Br J Dermatol 190: 988–991
Gruss C, Behrens St, Reuther T, Husebo L, Neumann N, Altmeyer P, Lehmann P, Kerscher M (1998) Kinetics of photosensitivity in bath-PUVA photochemotherapy. J Am Acad Dermatol 39: 443–446
Hagemann I, Proksch E (1996) Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol (Stockh) 76: 353–356
Hagers Handbuch der pharmazeutischen Praxis Bd. 8 (1993). Springer, Berlin Heidelberg New York, S 933–935
Hammarström S, Hamberg M, Samuelsson B, Duell E, Stawiski M, Voorhees JJ (1975) Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14 - eicostetraenoic acid, prostaglandin Ez,x in epidermis of psoriasis. Proc Natl Acad Sci USA 72: 5130–5134
Hannuksela M, Karvonen J (1984) Topical trioxsalen PUVA therapy. Acta Derm Venereol Suppl (Stockh) 113: 135–138
Hannuksela M, Karvonen J (1989) Carcinogenicity of trioxsalen bath PUVA. J Am Acad Dermatol 21: 813–814
Hannuksela A, Pukkala E, Hannuksela M (1996) Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. J Am Acad Dermatol 35: 685–689
Hecker D, Martinez J, Sapadin J, Patel B, Lebwohl N (1995) Effects of topical calcipotriene on transmission of ultraviolet light and effect of ultraviolet light on the stability of calcipotriene. J Invest Dermatol 104 Suppl: 659
Hulsebosch HJ, Ponec-Waelsch M (1972) The interaction of anthralin, salicylic acid and zinc oxide in pastes. Dermatologica 144: 287–293
Huuskonen H, Koulu L, Wilén G (1984) Quantitative determination of methoxsalen in human serum, suction blister fluid and epidermis by gas chromatography mass spectrometry. Photo-dermatology 1: 137–140
Jacques Y, Reichert U (1981) Effects of anthralin and analogues on growth and 3H thymidine incorporation in human skin fibroblasts. Br J Dermatol 105 Suppl 20: 45–48
Jong EMGJ de, Baadsgaard O (1998) Vitamin D: Rationale and potential mechanism of action. In: Roenigk HH, Maibach HI (eds). Psoriasis. Marcel Dekkers, New York Basel Hong Kong, pp 489–494
Kammerau B, Zesch A, Schäfer H (1975) Absolute concentrations of dithranol and triacetyldithranol in the skin layers after local treatment: in vivo investigations with four different types of pharmaceutical vehicles. J Invest Dermatol 64: 145–149
Kammerau B, Klebe U, Zesch A, Schäfer H (1976) Penetration, permeation and resorption of 8 methoxypsoralen. Arch Dermatol Res 255: 31–42
Kanzler MH, Gorsulowsky DC (1993) Efficacy of topical 5% liquor carbonis detergens vs its emollient base in the treatment of psoriasis. Br J Dermatol 129: 310–314
Kemény L, Gross E, Arenberger P, Ruzicka T (1991) Dithranol-induced down-regulation of 12(S)hydroxyeicosatetraenoic acid [12(S)-HETE] receptors in a human epidermal cell line. Arch Dermatol Res 283: 333–336
Kerkhof PCM van de (1998) An update on vitamin D3 analogues in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 11: 2–10
Kerkhof CPM van de, Hutschinson PE (1996) Topical use of calcipotriol improves outcome in acitretin treated patient with severe psoriasis vulgaris. Br J Dermatol Suppl 135: 30
Kerkhof CMP van de, Werfel T, Haustein UF, Luger T, Czarnetzki BM, Niemann R, Plänitz-Stenzel V (1996) Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo controlled, double blind study on efficacy and safety. Br J Dermatol 135: 758–765
Kerkhof P van de, Vleuten C van der, Gerritsen M, Glade C, Luger Th, Werfel Th, Klüss B (1997) Long term efficacy and safety of once daily treatment of chronic plaque psoriasis with tacalcitol ointment. Eur J Dermatol 7: 421–425
Kerscher M, Behrens St (1998) PUVA-Bad-und PUVA Cremetherapie. In: Plewig G, Wolf H (Hrsg). Fortschritte der praktischen Dermatologie und Venerologie. Springer, Berlin Heidelberg New York, S 359–364
Kerscher M, Volkenandt M, Plewig G (1993) Combination phototherapy of psoriasis with calcipotriol and narrow band UVB. Lancet 243: 923
Kerscher M, Lehmann P, Plewig G (1994) PUVA Bad Therapie Indikationen und praktische Durchführung. Hautarzt 45: 526–528
Kirkup ME, Sabroo RA, Kavanagh GM, Downs AMR, Sansom JE, Berker DAR de, Dunnill MGS, Kennedy CTG, Archer CB (1999) Twice daily versus once daily in patient dithranol for psoriasis. Br J Dermatol 141 Suppl 55: 72–73
Kokelj F, Plozzer C, Guadagnini A (1996) Topical tacalcitol reduces the total UVB dosage in the treatment of psoriasis vulgaris. J Dermatol Treatm 7: 265–266
Koo JYM, Gambia C, Lee J, Siebenlist J (1998) Vitamin D analogues in the treatment of psoriasis. In: Roenigk HH, Maibach HI (eds). Psoriasis, 3. Aufl. Marcel Dekkers, New York Basel Hong Kong, pp 497–506
Kraft St, Maibach HI, Shroot B (1998) Dithranol (Anthralin). In: Roenigk HH Jr, Maibach HI (eds). Psoriasis. Marcel Dekkers, New York Basel Hong Kong, pp 435–452
Kragballe K (1989) Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). Arch Dermatol 125: 1647–1652
Kragballe K (1992) Vitamin D analogues in the treatment of psoriasis. J Cell Biochem 49: 46–52
Kragballe K, Tore-Gjertzen B, Hoop D (1991) Double blind, right left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis. Lancet 337: 193–196
Lambelet P, Löliger J, Shroot B (1988) Role of free radicals in the mode of action of anthralin. Skin Pharmacol 1: 115–121
Lawlor F, Hindons C (1982) Allergy to dithranol. Contact Dermatitis 8: 137–138
Lawrence GM, Finnen MI, Shuster S (1984) Effect of coal tar on cutaneous aryl hydrocarbon hydroxylase induction and anthralin irritancy. Br J Dermatol 110: 671–675
Lebwohl M, Hecker D, Martinez J, Sapadin A, Patel B (1997) Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol 37: 93–95
Lee DY, Cho KH, Minn KW, Son YS (1996) Effects of calcipotriol (MC 903) on proliferation and differentiation of cultured human epidermal keratinocytes. Korean J Dermatol 34: 942–952
Lehmann P (1998) Vitamin D-Mono-und Kombinationstherapie. In: Garbe G, Rassner G (Hrsg). Dermatologie Leitlinien und Qualitätssicherung für die Diagnostik und Therapie. Springer, Berlin Heidelberg New York, S 611–612
Lindelöf B, Sigurgeirsson B, Tegner E, Larkö O, Berne B (1992) Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report. Arch Dermatol 128: 1341–1344
Lindelöf B, Sigurgeirsson B, Tegner E, Larkö 0, Johannesson A, Berne B, Ljunggren B, Andersson T, Molin L, Nylander-Ljungquist E, Emtestam L (1999) PUVA and cancer risk: the Swedish follow up study. Br J Dermatol 141: 108–112
Lowe NJ, Breeding J (1981) Anthralin - Different concentration effects on epidermal cell DNA synthesis rates in mice and clinical responses in human psoriasis. Arch Dermatol 117: 698–700
Lowe JN, Weingarten D, Bourget R, Moy SL (1986) PUVA therapy for psoriasis: comparison of oral and bath water delivery. J Am Acad Dermatol 14: 754–760
Lüftl M, Degitz K, Plewig G (1997) Psoralen bath plus UV A therapy. Possibilities and limitations. Arch Dermatol 133: 1597–1603
Matsunaga T, Yamamato M, Mimura H (1990) 1,25 (R) Dihydroxyvitamin D 3, a novel active form of vitamin D 3 with high activity for inducing epidermal differentiation but decreased hypercalcaemic activity. J Dermatol 17: 135–142
Merk HF, Bickers DR (1992) Dermatopharmakologie und Dermatotherapie. Blackwell Wissenschaft, S 383–412
Miller RA (1982) Psoralens and UV-A-induced stellate hyperpigmented freckling. Arch Dermatol 118: 619–620
Mohn L and Calcipotriol UVB study group (1999) Topical calcipotriol combined with photo-therapy for psoriasis - the results of two randomized trials and a review of the literature. Dermatology 198: 375–381
Mommers JM, Castelijns FACM, Seegers BAMPA, Rossum MM van, Hooijdonk CAEM van, Erp PEJ van, Kerkhof PCM van (1998) The effect of long-term treatment with tacalcitol on the psoriatic epidermis. A flow cytometric analysis. Br J Dermatol 139: 468–471
Mommers TM, Meulen AC ter, Erp PEJ van, Kerkhof PCM van de (1999) Influence of tacalcitol on cell cycle kinetics of human keratinocytes following standardized injury. Skin Pharmacol Appl Skin Physiol 12: 174–181
Monk BE, Mehir ME, Clement MT, Penmbroke AC, Du Vivier A (1988) Anthralin-corticosteroid combination therapy in the treatment of plaque psoriasis. Arch Dermatol 124: 548–550
Müller K, Gawlik I (1996) Inactivation of mouse epidermal 12 - lipoxygenase by anthralin - im-plications for the role of oxygen radicals. Biochem Pharmacol 51: 1173–1179
Müller K, Kappus (1988) Hydroxyl radical formation by dithranol. J Biochim Pharm 37: 4277–4286
Müller K, Prinz H (1997) Antipsoriatic anthrones with modulated redox properties 4. Synthesis and biological activity of novel 9,10-dihydro-9-oxo-2-anthracene-carboxylic and-hydroxamic acids. J Med Chem 4o: 2780–2787
Müller K, Seidel M, Braun C, Ziereis K, Wiegrebe W (1991) Dithranol, glucose phosphate dehy-drogenase inhibition and active oxygen species. Arzneimittelforschung 41: 1176–1181
Müller R, Naumann E, Detmar M, Orfanos CE (1987) Stabilität von Cignolin (Dithranol) in teer-haltigen Salben mit und ohne Salicylsäurezusatz. Hautarzt 38: 107–111
Nakayama J, Kiryu H, Urabe K, Matsuo S, Shibata S, Koga T, Furue M (1999) Vitamin D3 analogues improve café au lait spots in patients with van Recklingshausen’s disease: experimental and clinical studies. Eur J Dermatol 9: 202–206
Neild VS, Scott LV (1982) Plasma levels of 8- methoxypsoralen in psoriatic patients recieving topical 8 methoxypsoralen. Br J Dermatol 106: 199–203
Ortonne JP (1994) New therapeutic modality by calcipotriol and betamethason dipropionate. Nouv Dermatol 13: 746–751
Parslew R, Friedmann PS (1999) The irritancy of anthralin is inhibited by repeat application of a subirritant concentration. Br J Dermatol 141: 469–474
Peters DC, Balfour JA (1997) Tacalcitol. Drugs 54: 265–271
Plewig G, Hofmann C, Braun-Falco O (1978) Photoallergic dermatitis from 8-methoxypsoralen. Arch Dermatol Res 261: 201–211
Plumier E, Wappes B, Wiegrebe W (1984) Incorporation of 3H thymidine into DNA: inhibition by dithranol and its di-and triacetate. Arch Dermatol Res 276: 406–408
Poskitt BL, Wilkinson JD, Wojnarowska FT (1993) Patchy speckled PUVA pigmentation. J R Soc Med 86: 665–666
Prins M, Swinkels QJ, Kolkman EGW, Wuis EW, Hekster YA, Valk PGM van de (1998) Skin irritation by dithranol cream - a blind study to assess the role of the cream formulation. Acta Derm Venereol (Stockh) 78: 262–265
Przybilla B, Kaudewitz P (1987) Ambulante äußerliche Behandlung der Psoriasis vulgaris: Vergleich der Wirksamkeit einer Dithranol-und einer Glukokortikosteroidhaltigen Zubereitung. Z Hautkr 63: 60–62
Puschmann M (1983) Experimentelle Untersuchungen zur Erythembildung an der gesunden Haut durch Anthralin. Arztl Kosmetol 13: 207–214
Ramsay CA, Berth-Jones J, Brundin G, Cunliffe WJ, Dubertret L, Kerkhof PCM van de, Wegmann E (1994) Long term use of topical calcipotriol in chronic plaque type psoriasis. Dermatology 189: 260–264
Reichert U, Jaques Y, Grangeret M, Schmidt R (1985) Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes. J Invest Dermatol 84: 130–134
Reuther T, Gruss C, Behrens S, Kobyletzki G, Neumann N, Lehmann P, Kerscher M (1997) Time course of 8 methoxypsoralen induced skin photosensitization in PUVA bath photo chemotherapy. Photodermatol Photoimmunol Photomed 13: 193–196
Reuther T, Behrens S, Kobyletzki G, Altmeyer P, Neumann N, Lehmann P, Kerscher M (1998) Kinetik der Photosensibilisierung für die Balneophotochemotherapie mit 8 Methoxypsoralen In: Garbe C, Rassner G (Hrsg). Dermatologische Leitlinien und Qualitätssicherung für die Diagnostik und Therapie. Springer, Berlin Heidelberg New York, S 563–566
Rie MAD, Eendenburg JP van, Versnick AC, Stolk IMI, Bos JD, Westerhof W (1995) A new psoralen-containing gel for topical PUVA therapy: development and treatment results in patients with palmoplantar and plaque type psoriasis and hyperkeratotic eczema. Br J Dermatol 132: 964–969
Röcken M, Messer G, Plewig G (1998) Treatment of psoriasis with vitamin D3 derivates and 311 nm UVB. J Dermatol Treatm 9 Suppl 3: 37–40
Roenigk HH Jr (1998) PUVA and skin cancer. In: Roenigk HH jr, Maibach HI (eds). Psoriasis. Marcel Dekkers, New York Basel Hong Kong, pp 577–586
Ruzicka Th, Vitto A, Printz MP (1983) Epidermal arachidonate lipoxygenase. Biochim Biophys Acta 751: 359–374
Sae Melo Th, Dubertret L, Prognon P, Gond A, Mahuzier G, Santus R (1983) Physicochemical properties and stability of anthralin in model systems and human skin. J Invest Dermatol 80: 1–6
Saihan EM, Albano J, Burton JL (1980) The effect of steroid and dithranol therapy on cyclic nucleotides in psoriatic epidermis. Br J Dermatol 102: 565–569
Scarpa C (1996) Tacalcitol ointment is an efficacious and well tolerated treatment for psoriasis. J Eur Art Dermatol Venereol 6: 142–146
Scarpa C, Kokelj F, Plozzer C, Lavaroni G, Torsello P (1997) Efficacy and tolerability of tacalcitol administered once daily in the treatment of psoriasis vulgaris (double blind, randomized placebo controlled Italian multicenter study). G Ital Dermatol Venereol 132: 335–338
Schäfer H, Zesch A, Stüttgen G (1981) Skin permeability. In: Stüttgen G, Spier HW, Schwarz E (Hrsg). Handbuch der Haut-und Geschlechtskrankheiten, Ergänzungswerk Bd 1/4b. Springer, Berlin Heidelberg, S 541–886
Schalla W, Bauer E, Schaefer H (1981) Skin permeability of anthralin. Br J Dermatol 105 Suppl 20: 104–108
Schaltegger A, Brunner F, Steiger W, Krebs A (1987) Dithranol: further investigations on the structure-activity relationship - The new series of the 10 - mono-alkyldithranol derivates. Dermatologica 175: 136–141
Schauder S, Mahrle G (1982) Kombinierte Einstundentherapie der Psoriasis mit Anthralin und UV-Licht. Hautarzt 33: 206–209
Schempp CM, Schöpf E, Simon JC (1996) Phototesting in bath PUVA: marked reduction of 8 methoxypsoralen (8-MOP) activity within one hour after an 8-MOP bath. Photodermatol Photoimmunol Photomed 12: 100–102
Schröder JM (1986) Anthralin (1,8-dihydroxyanthrone) is a potent inhibitor of leukotriene pro-duction and LTB4-w oxidation by human neutrophils. J Invest Dermatol 87: 624–629
Schulze JH (1984) Unterdrückung des Cignolin-bedingten Erythems durch Teer. Z Hautkr 59: 659–662
Schulze HJ, Steigleder GK (1984) Erfahrungen bei Halbseitenbehandlung mit Teerzusatz zu Cignolin - Salicylsäure - weißer Vaseline (CVS -)Therapie (TCSV) der Psoriasis vulgaris. Z Hautkr 59: 654–656
Seidenari S, Magni R, Gianetti A (1997) Assessment of the activity of tacalcitol on psoriatic plaque by means of colorimetry and high-frequency ultrasound: a double-blind intrasubject half-side right-left comparison with beta-metasone valerate and placebo. Skin Pharmacol l0: 40–47
Shepard SE, Schregenberger N, Dummer R, Pannizon R (1998) Comparison of 8-MOP aqueous bath and 8-MOP ethanolic lotion (melanadinie) in local PUVA therapy. Dermatology 197: 25–30
Shroot B, Brown C (1986) Free radicals in skin exposed to dithranol and its derivates. Arzneimittelforschung 36: 1253–1255
Squire B (1877) Chrysophanic acid as a remedy in skin disease. Med J 1: 199–200
Staberg B, Roed-Petersen J, Menné J (1989) Efficacy of topical treatment in psoriasis with MC 903 a new vitamin D analogue. Acta Derm Venereol (Stockh) 69: 147–150
Stege H, Berneburg M, Ruzicka Th, Krutmann J (1997) Creme PUVA Photochemotherapie. Hautarzt 48: 89–93
Streit V, Wedow O, Christophers E (1994) Innovative Balneophototherapie mit reduziertem Badevolumina. Hautarzt 45: 140–144
Swanbeck G, Lundquist P (1972) Ultrastructural changes of mitochondria in dithranol-treated psoriatic epidermis. Acta Derm Venereol (Stockh) 52: 94–98
Takashima A, Yamamoto K, Kimura S, Takakuwa Y, Micuno N (1991) Allergic contact and photocontact dermatitis due to psoralens in patients with psoriasis treated with topical PUVA. Br J Dermatol 124: 37–42
Taube KH, Fiedler H, Wohlrab W, Wozniak KD (1985) Untersuchungen zur Kurzzeittherapie der Psoriasis vulgaris mit Dithranol unter Harnstoffzusatz. Dermatol Monatsschr 171: 650–653
Thaci D, Berna A, Holzmann H, Kaufmann R (1998) Tacalcitol in combination with UVB-in vitro effects. J Dermatol Treatm 9, Suppl 3: 31–36
Tham SM, Lun KC, Cheong WK (1994) A comparative study of calipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 131: 673–677
Thoma K, Holzmann Ch (1997) Dithranol Präparate. Dtsch Apoth Z 137: 54–67
Trasciatti S, Canali S, Palmubo R, Zeppa S (1993) Pharmacokinetics of 3H tacalcitol in psoriatic patients In: Book of Abstracts 3th Congress of the European Academy of Dermatology and Venereology Copenhagen, p 21
Unna EG (1916) Cignolin als Heilmittel der Psoriasis. Dermatol Monatsschr 62: 116–137
Vallat PV, Gilleaudeau P, Battat L, Wolfe J, Nabeya R, Heftier N, Hodak E, Gottlieb AB, Krueger JG (1994) PUVA bath therapy strongly suppresses immunological and epidermal acitivation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 180: 283–296
Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB (1997) Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol-A double blind trial. Br J Dermatol 137: 581–586
Vleuthen CHM van der, Gerritsen MJP, Jong EMGJ de, Elbers M, Jongh GJ de, Kerkhof PCM van de (1986) A novel dithranol formulation (Micanol): the effects of monotherapy and UVB combination therapy on epidermal differentiation, proliferation and cutaneous inflammation in psoriasis vulgaris. Acta Derm Venereol (Stockh) 76: 387–391
Wang JCT, Pätel BG, Ehmann CW, Lowe N (1987) The release and percutaneous permeation of anthralin products, using clinically involved and uninvolved psoriatic skin. J Am Acad Dermatol 16: 812–821
Wiegrebe W, Retzow A, Plumier E, Ersoy N, Garbe A, Faro HP, Kunert R (1984) Dermal absorption and metabolism of the antipsoriatic drug dithranol triacetate. Arzneimittelforschung 34: 48–51
Willis I, Harris DR (1973) Resistant psoriasis. Combined methoxalen-anthralin therapy. Arch Dermatol 107: 358–362
Wohlrab W (1977) Die therapeutische Harnstoffwirkung auf die Haut. Dermatologica 155: 97109
Yip J, Goodfield M (1991) Contact dermatitis from MC 903, a topical vitamin D3 analogue. Contact Dermatitis 25: 139–140
Youn JI, Park BS, Chung JH, Lee JH (1997) Photoprotective effect of calcipotriol upon skin photo-reaction UVA and UVB. Photodermatol Photoimmunol Photomed 13: 109–113
Zwart AJ de, Jong EMGJ de, Kerkhof PCM van de (1992) Topical application of dithranol on normal skin induces epidermal hyperproliferation and increased Ks8.12 binding Skin Pharmacol 5: 34–40
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gloor, M. (2000). Dithranol, Vitamin D3-Analoga und 8-Methoxypsoralen. In: Dermatologische Externatherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58308-7_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-58308-7_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63533-5
Online ISBN: 978-3-642-58308-7
eBook Packages: Springer Book Archive